Related Experiment Video

Updated: Jan 23, 2026

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
09:22

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

Published on: November 4, 2015

12.6K

Surgical treatment of chronic thromboembolic pulmonary hypertension

Matúš Nižňanský, David Ambrož, Tomáš Prskavec

    Vnitrni Lekarstvi
    |June 6, 2019
    PubMed

    Keywords:
    balloon angioplastychronic thromboembolic pulmonary hypertensionpulmonary endarterectomyriociguatsurgical techniquetreatment options

    More Related Videos

    Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension07:41

    Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

    Published on: March 17, 2022

    3.4K
    Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

    Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

    Published on: June 27, 2025

    759

    Related Concept Videos

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    580
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
    449
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    475
    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

    Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
    Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
    599
    Pulmonary Hypertension: Classification and Pathogenesis01:30

    Pulmonary Hypertension: Classification and Pathogenesis

    Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
    There are various classifications for PH, each relating to different underlying causes and also...
    599
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    469